G1 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-47.97	-147.56	-148.35	-99.25	-122.45	-85.29	-64.88	-34.7	-21.69
Depreciation & Amortization	0.51	0.53	0.47	0.58	0.36	0.18	0.09	0.07	0.04
Share-Based Compensation	14.51	20.59	22.32	18.77	16.45	10.23	3.39	1.39	0.39
Other Operating Activities	-5.39	-2.18	-6.54	-3.84	6.07	0.58	6.12	3.69	5.99
Operating Cash Flow	-38.34	-128.62	-132.11	-83.74	-99.57	-74.31	-50.52	-25.14	-13.85
Capital Expenditures	0	-0.51	0	0.15	-2.72	-0.71	-0.29	-0.25	-0.09
Change in Investments	2.81	-50.02	0	0	0	0	0	0	0
Investing Cash Flow	2.81	-50.53	0	0.15	-2.72	-0.71	-0.29	-0.25	-0.09
Share Issuance / Repurchase	0.06	52.54	92.27	2.31	2.71	341.39	108.72	0.01	0.05
Debt Issued / Paid	-26.69	0	53.64	19.38	0	0	0	0	0
Other Financing Activities	-0.28	-0.04	-0.05	-	-	-0.89	-1.4	49.75	33.12
Financing Cash Flow	-26.91	52.5	145.86	21.69	2.71	340.49	107.32	49.76	33.18
Net Cash Flow	-62.44	-126.65	13.76	-61.9	-99.58	265.48	56.51	24.37	19.24
Free Cash Flow	-38.34	-129.13	-132.11	-83.59	-102.29	-75.02	-50.81	-25.39	-13.93
Free Cash Flow Margin	-46.46%	-251.70%	-419.71%	-184.59%	-	-	-	-	-2668.97%
Free Cash Flow Per Share	-0.74	-2.96	-3.15	-2.21	-2.73	-2.25	-2.79	-17.07	-10.36

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).